Results 141 to 150 of about 1,891 (175)
Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin
Toxicon, 2001 The neutralization of botulinum toxin serotype A with polyclonal equine antitoxin was studied in isolated mouse hemidiaphragms and compared to the same action in live mice. The biological activity of the toxin in the isolated muscle could be markedly reduced with excess antitoxin, estimated as 3:1 molar ratios of IgG Ab:toxin or better.
Robert E. Sheridan +4 more
openalex +3 more sources
Development of an Avian Antitoxin to Type A Botulinum Neurotoxin
, 1993 Most commercially available antitoxins and antivenoms are raised in horses and purified by bulk fractionation techniques. These preparations frequently elicit deleterious side effects that compromise their efficacy and the treatment of intoxication or envenomation.
Bruce S. Thalley +5 more
openalex +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin
Clinical Neuropharmacology, 2022Objective Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe.
Ozge Gonul Oner +3 more
openaire +2 more sources
Source of Botulinum Antitoxin Products Needs Clarifying
Pediatric Annals, 2010 Ryan Fagan, CAPT Hye-Joo Kim
openalex +2 more sources
Antitoxin therapy for botulinum intoxication
Reviews in Medical Microbiology, 2001Botulinum toxin is the most toxic substance known to mankind. It is involved in infant botulism, classical food-borne botulism, wound botulism, and is a threat in biological warfare or bioterrorism.
Carl N. Mayers +2 more
openaire +1 more source
A review of WHO International Standards for botulinum antitoxins
Biologicals, 2006Clostridium botulinum produces the most potent known toxins, with seven distinct serotypes currently defined (A-G). These toxins can cause a life threatening systemic toxicity whether through natural causes such as food poisoning, infant botulism, wound botulism, or through use as bio-terror agents (e.g. inhalational botulism). It was realised early on
R G A, Jones, M J, Corbel, D, Sesardic
openaire +2 more sources
Infant botulism in Australia: availability of human botulinum antitoxin for treatment
Medical Journal of Australia, 2010We report the first Australian case of treatment of infant botulism with a human botulinum antitoxin developed in the United States by the California Department of Public Health. Our patient's clinical improvement was rapid, and although the product is expensive, cost-analysis supports the economical viability of its use.
May, M. L. A. +2 more
openaire +2 more sources
Clinical Immunology, 2010
To produce a vaccine suitable for human use, a recombinant non His-tagged isoform of the Hc domain of botulinum neurotoxin serotype F (rFHc) was expressed in Escherichia coli and purified by sequential chromatography. The rFHc was evaluated as a subunit vaccine candidate in mouse model of botulism.
Yun-Zhou, Yu +11 more
openaire +2 more sources
To produce a vaccine suitable for human use, a recombinant non His-tagged isoform of the Hc domain of botulinum neurotoxin serotype F (rFHc) was expressed in Escherichia coli and purified by sequential chromatography. The rFHc was evaluated as a subunit vaccine candidate in mouse model of botulism.
Yun-Zhou, Yu +11 more
openaire +2 more sources
An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins
Vaccine, 2017Botulism therapy relies on passive immunization with antitoxin. The mouse neutralization test is the only pharmacopeia assay to measure the potency of antitoxin preparations. Herein, we present an in vitro cell-based assay for the measurement of pharmaceutical type A antitoxin potency. Accuracy, reproducibility and compatibility with the mouse bioassay
Amram, Torgeman +8 more
openaire +2 more sources